Bioequivalence Standards For Testosterone Gel At Issue In Perrigo v. FDA Suit
This article was originally published in The Pink Sheet Daily
Executive Summary
Perrigo’s 505(b)(2) product lacks a therapeutic equivalence rating more than a year after approval; firm says FDA found it bioequivalent to AbbVie’s AndroGel.